Casellas Caro, Manel
Hidalgo, María Jesús Cancelo
García-Erce, José Antonio
Baquero Úbeda, José Luis
Torras Boatella, Maria Glòria
Gredilla Díaz, Elena
Ruano Encinar, Margarita
Martín Bayón, Israel
Nicolás Picó, Jordi
Arjona Berral, José Eduardo
Muñoz Solano, Alberto
Jiménez Merino, Silvia
Cerezales, Mónica
Cuervo, Jesús
Funding for this research was provided by:
Vifor Pharma España S.L.U.
Article History
Received: 2 September 2021
Accepted: 16 February 2022
First Online: 25 February 2022
Declarations
:
: In accordance with national regulations in force, ethics approval and consent to parcipate were not required (Law LEY 14/2007, de 3 de julio, de Investigación biomédica; and Orden SAS/3470/2009, de 16 de diciembre, por la que se publican las directrices sobre estudios posautorización de tipo observacional para medicamentos de uso humano).
: Not applicable.
: M.C.C., M.J.C.H., J.L.B.U., M.G.T.B., E.G.D., M.R.E, I.M.B, J.N.P., J.E.A.B., A.M.S. and Axentiva Solutions S.L. received consulting fees from Vifor Pharma España S.L.U. J.A.G.E has received research funding, consulting fees, reimbursment for speaking at conferences, or travel grants from Vifor Pharma, Sandoz, Zambon, Octapharma, CSL-Behring, and Fresenius. S.J.M. is an employee at Vifor Pharma España S.L.U. MC and JC work for a consulting firm being hired by Vifor Pharma España. The rest of the authors declare no conflict of interests.